Beqalzi Becomes First BCL-2 Inhibitor Approved for Mantle Cell Lymphoma

A recently licensed targeted anticancer drug called Beqalzi (sonrotoclax) is used to treat refractory or relapsed mantle cell lymphoma (MCL), a rare kind of non-Hodgkin lymphoma. It is a member of the BCL-2 inhibitor class, which functions by preventing the BCL-2 protein, which is essential for cancer cells to survive. Beqalzi causes apoptosis, or programmed cell death, and slows the growth of tumors by blocking this protein. In individuals who had previously undergone various treatments, such as BTK inhibitors, the medication has demonstrated encouraging clinical results. To reduce the possibility of tumor lysis syndrome (TLS), a potentially dangerous side effect, beqalzi is taken orally with a progressive dose increase. Its clearance signifies advancements in contemporary cancer treatment centered on selective action against malignant cells and offers a significant new targeted therapy option for cases of lymphoma that are challenging to treat. After at least two previous systemic treatments, including a BTK inhibitor, people with relapsed or refractory mantle cell lymphoma (MCL) may be treated with Beqalzi (generic name: sonrotoclax), an oral next-generation BCL-2 inhibitor. It promotes the programmed death of malignant lymphoma cells by specifically inhibiting the anti-apoptotic BCL-2 protein. Based on the findings of the phase 1/2 BGB-11417-201 clinical trial, which included patients with extensively pretreated MCL, the U.S. FDA granted the medication rapid approval in May 2026. Beqalzi had a 52% overall response rate in the research, with 16% of patients showing full responses and a median response duration of 15.8 months. Food and Drug Administration of the United States +2 To lower the risk of tumor lysis syndrome (TLS), a significant treatment-related safety issue, beqalzi is taken orally once day with food on a four-week dose ramp-up regimen. Fatigue, pneumonia, diarrhea, edema, fever, and upper respiratory infections are typical side effects. For patients with few therapeutic alternatives following the failure of previous medications, Beqalzi, the first BCL-2 inhibitor specifically licensed for mantle cell lymphoma, offers a major advancement in targeted therapy.